MX370680B - Polimorfos de arry-380, un inhibidor selectivo de herb2 y composiciones farmacéuticas que los contienen. - Google Patents

Polimorfos de arry-380, un inhibidor selectivo de herb2 y composiciones farmacéuticas que los contienen.

Info

Publication number
MX370680B
MX370680B MX2014004553A MX2014004553A MX370680B MX 370680 B MX370680 B MX 370680B MX 2014004553 A MX2014004553 A MX 2014004553A MX 2014004553 A MX2014004553 A MX 2014004553A MX 370680 B MX370680 B MX 370680B
Authority
MX
Mexico
Prior art keywords
polymorphs
herb2
arry
inhibitor
selective
Prior art date
Application number
MX2014004553A
Other languages
English (en)
Other versions
MX2014004553A (es
Inventor
M Lindemann Christopher
T Corson Donald
J Watson Daniel
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2014004553A publication Critical patent/MX2014004553A/es
Publication of MX370680B publication Critical patent/MX370680B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente proporciona polimorfos de N4-(4-([1,2,4]triazolo[1,5-a ]piridin-7-iloxi)-3-metilfenil)-N6-(4,4-dimetil-4,5-dihidrooxazol -2-iI)quinazolin-4,6-diamina. También se describen procedimientos para preparar los polimorfos y composiciones farmacéuticas que comprenden los polimorfos.
MX2014004553A 2011-10-14 2012-10-12 Polimorfos de arry-380, un inhibidor selectivo de herb2 y composiciones farmacéuticas que los contienen. MX370680B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161547615P 2011-10-14 2011-10-14
US201261606185P 2012-03-02 2012-03-02
PCT/US2012/060138 WO2013056183A1 (en) 2011-10-14 2012-10-12 Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them

Publications (2)

Publication Number Publication Date
MX2014004553A MX2014004553A (es) 2015-02-12
MX370680B true MX370680B (es) 2019-12-19

Family

ID=47471982

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014004553A MX370680B (es) 2011-10-14 2012-10-12 Polimorfos de arry-380, un inhibidor selectivo de herb2 y composiciones farmacéuticas que los contienen.
MX2019010083A MX2019010083A (es) 2011-10-14 2014-04-14 Polimorfos de arry-380, un inhibidor selectivo de herb2 y composiciones farmaceuticas que los contienen.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019010083A MX2019010083A (es) 2011-10-14 2014-04-14 Polimorfos de arry-380, un inhibidor selectivo de herb2 y composiciones farmaceuticas que los contienen.

Country Status (17)

Country Link
US (6) US9168254B2 (es)
EP (1) EP2766363A1 (es)
JP (4) JP2014530243A (es)
KR (2) KR102061917B1 (es)
CN (1) CN104011047A (es)
AU (1) AU2012323890A1 (es)
BR (1) BR112014009084B1 (es)
CA (1) CA2852060A1 (es)
CL (1) CL2014000932A1 (es)
CO (1) CO6960548A2 (es)
CR (1) CR20140219A (es)
IL (1) IL232062A0 (es)
MX (2) MX370680B (es)
RU (1) RU2629116C2 (es)
SG (1) SG11201401460PA (es)
UA (1) UA116875C2 (es)
WO (1) WO2013056183A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201401459YA (en) 2011-10-14 2014-07-30 Array Biopharma Inc Solid dispersions of a erb2 (her2) inhibitor
CA2852060A1 (en) * 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
EP4252855A3 (en) * 2012-03-23 2023-11-15 Array Biopharma, Inc. Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
CN110446495B (zh) 2017-02-17 2023-09-05 特维娜有限公司 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
MA49059A (fr) 2017-04-28 2021-03-24 Seagen Inc Traitement des cancers positifs à her2
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
CA3135555C (en) 2019-04-02 2023-09-19 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
MX2022004699A (es) 2019-10-21 2022-08-08 Seagen Inc Metodos de tratamiento del cancer de mama con sobreexpresion de her2 con tucatinib en combinacion con capecitabina y trastuzumab.
US20220387618A1 (en) 2019-11-15 2022-12-08 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
MX2022014886A (es) 2020-05-29 2023-01-04 Seagen Inc Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab y una quimioterapia a base de oxaliplatino.
CA3189333A1 (en) 2020-07-29 2022-02-03 Seagen Inc. Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist
JP2023546729A (ja) * 2020-10-27 2023-11-07 トレベナ・インコーポレイテッド デルタオピオイドモジュレーターの結晶形及び非晶形

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
SG148857A1 (en) 2002-03-13 2009-01-29 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
CN102432552B (zh) 2003-08-14 2016-01-20 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN1882573A (zh) 2003-09-16 2006-12-20 阿斯利康(瑞典)有限公司 作为酪氨酸激酶抑制剂的喹唑啉衍生物
GB0321648D0 (en) 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
CA2755268C (en) * 2005-11-15 2013-12-31 Array Biopharma, Inc. Erbb inhibitors
CA2852060A1 (en) * 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
SG11201401459YA (en) 2011-10-14 2014-07-30 Array Biopharma Inc Solid dispersions of a erb2 (her2) inhibitor
EP4252855A3 (en) 2012-03-23 2023-11-15 Array Biopharma, Inc. Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer

Also Published As

Publication number Publication date
BR112014009084A2 (pt) 2017-05-09
AU2012323890A1 (en) 2014-05-29
US20180140603A1 (en) 2018-05-24
EP2766363A1 (en) 2014-08-20
US20140243361A1 (en) 2014-08-28
KR20140082806A (ko) 2014-07-02
KR20200003245A (ko) 2020-01-08
CA2852060A1 (en) 2013-04-18
US10765678B2 (en) 2020-09-08
RU2014119269A (ru) 2015-11-20
MX2014004553A (es) 2015-02-12
US20160175309A1 (en) 2016-06-23
JP2018177822A (ja) 2018-11-15
SG11201401460PA (en) 2014-09-26
JP2017128612A (ja) 2017-07-27
US10143692B2 (en) 2018-12-04
KR102061917B1 (ko) 2020-01-02
RU2629116C2 (ru) 2017-08-24
CO6960548A2 (es) 2014-05-30
CN104011047A (zh) 2014-08-27
UA116875C2 (uk) 2018-05-25
US20230241066A1 (en) 2023-08-03
IL232062A0 (en) 2014-05-28
US9889134B2 (en) 2018-02-13
US11571424B2 (en) 2023-02-07
CR20140219A (es) 2014-07-11
MX2019010083A (es) 2019-11-21
US20210077493A1 (en) 2021-03-18
JP2016033166A (ja) 2016-03-10
BR112014009084B1 (pt) 2021-09-21
WO2013056183A1 (en) 2013-04-18
CL2014000932A1 (es) 2014-07-11
JP2014530243A (ja) 2014-11-17
US9168254B2 (en) 2015-10-27
US20190125749A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
MX2019010083A (es) Polimorfos de arry-380, un inhibidor selectivo de herb2 y composiciones farmaceuticas que los contienen.
MY169072A (en) Solid dispersions of a erb2 (her2) inhibitor
IL266510B (en) History of aminopyrimidines, their preparation and pharmaceutical preparations containing them
IL231226A (en) Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases
MX349004B (es) Nuevos compuestos.
MX336214B (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
WO2013004995A8 (en) Pyrimidinone compounds and their use
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
WO2012021715A3 (en) Stable formulations of linaclotide
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
IL229260A0 (en) Preparations, methods and systems for respiratory administration of two or more active agents
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
HK1187838A1 (zh) 胡桐素及胡桐素衍生物和類似物的藥物組合物及其製備方法
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
WO2012107890A3 (en) Crystal forms of lurasidone chlorhydrate
NZ630033A (en) Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl)urea hydrochloride
WO2012116254A3 (en) Chrysophaentin analogs that inhibit ftsz protein
WO2013155465A8 (en) Substituted xanthine derivatives
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
WO2012139074A3 (en) Migrastatins and uses thereof
WO2011092564A3 (en) Process for the preparation of temsirolimus and its intermediates
IL218764A (en) Crystalline lupilopinic acid and the process for its preparation, its uses, and its pharmaceutical preparations
MX351994B (es) Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico.
PL2497774T3 (pl) Pochodne dihydro-oksazolobenzodiazepinonu, sposoby ich wytwarzania i kompozycje farmaceutyczne zawierające te związki

Legal Events

Date Code Title Description
FG Grant or registration